As per MRFR analysis, the India Transthyretin Amyloidosis Market Size was estimated at 335 (USD Million) in 2023. The India Transthyretin Amyloidosis Market Industry is expected to grow from 365(USD Million) in 2024 to 847 (USD Million) by 2035. The India Transthyretin Amyloidosis Market CAGR (growth rate) is expected to be around 7.953% during the forecast period (2025 - 2035).
Due to the growing awareness and diagnosis of transthyretin amyloidosis (ATTR), a disorder that is frequently underdiagnosed, the India Transthyretin Amyloidosis Market is seeing notable developments. More patients are being seen as a result of healthcare providers detecting ATTR early because of the improved diagnostic facilities and developments in medical imaging technologies. The desire for focused therapies and customized treatment choices for this uncommon ailment is being influenced by the increased awareness among medical professionals and the general public, which is causing a significant change in the paradigm of therapy.
The ongoing efforts to improve healthcare affordability and accessibility are creating new opportunities in the Indian market. Programs to enhance the identification and treatment of uncommon diseases, such as ATTR, are being implemented by the Indian government and other health organizations. Pharmaceutical businesses and healthcare professionals have a greater chance of introducing novel therapies and locally tailored healthcare solutions that specifically address the demands of the Indian people as a result of this. Furthermore, public-private sector partnerships are anticipated to improve this field's research and development activities, meeting unmet medical requirements.
The number of clinical studies in India that are concentrating on new treatments for ATTR has increased recently, which indicates that both domestic and foreign companies are committed to serving the Indian market. New drug approvals for rare diseases are receiving increased support from the regulatory framework, which creates a favorable climate for market participants. Telemedicine and digital health technologies are also becoming more popular because they make it simpler for patients to receive care and consultations from a distance, which enhances patient outcomes and treatment compliance overall. Overall, these changing patterns and factors are positioning the transthyretin amyloidosis market in India for growth.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The increasing incidence of Transthyretin Amyloidosis (ATTR) in India is significantly driving the India Transthyretin Amyloidosis Market Industry. Recent data from the Ministry of Health and Family Welfare reports that approximately 1 in every 1000 individuals over the age of 60 years may be affected by amyloidosis. As India's elderly population is projected to reach 340 million by 2050, this translates to an estimated increase of 340,000 potential cases of Transthyretin Amyloidosis.This increase prompts the need for dedicated healthcare services and treatment options, leading to growth in the overall market. Prominent organizations such as the All India Institute of Medical Sciences (AIIMS) are actively researching advanced therapies and treatment protocols for ATTR, further promoting market development.
The India Transthyretin Amyloidosis Market Industry is experiencing growth driven by advancements in treatment options. The introduction of novel therapeutic agents, such as TTR stabilizers and gene silencing strategies, is enhancing treatment efficacy and patient outcomes. According to ClinicalTrials.gov, there are currently over 15 ongoing clinical trials in India assessing novel therapies for ATTR, indicating a surge in Research and Development (R&D) activities.Organizations like the Indian Council of Medical Research (ICMR) are supporting these trials, highlighting the increasing focus on innovative treatments that can lead to better management of ATTR and serve a growing patient population.
The Indian government has been increasingly focusing on policies and initiatives aimed at better management of rare diseases, including Transthyretin Amyloidosis. The National Health Policy of India emphasizes enhancing healthcare access and support systems for patients with rare diseases, encouraging pharmaceutical companies to invest in the India Transthyretin Amyloidosis Market Industry. In 2022, the government established special funds to support research and promote access to medications for patients suffering from rare diseases, which is expected to alleviate treatment costs associated with ATTR.This proactive approach reflects the government's commitment to improving healthcare outcomes and presents significant opportunities for market players.
The India Transthyretin Amyloidosis Market, particularly within the Disease segment, reflects a growing awareness and need for treatment options pertaining to conditions like Transthyretin (TTR) Familial Amyloid Polyneuropathy. This specific condition is caused by the accumulation of transthyretin proteins, leading to significant neurological damage and various systemic issues. In India, the incidence of TTR Familial Amyloid Polyneuropathy is underscored by a need for precise diagnostic tools and effective therapeutic interventions. As healthcare infrastructure in India advances, there is a noticeable shift towards developing targeted treatments, which is supported by increasing research initiatives and healthcare investments.
This segment has gained importance not only because of the rising patient population but also due to the collaboration between pharmaceutical companies and research institutions that aim to enhance patient care. Moreover, the government policies promoting rare disease management have laid a foundation that promotes therapy accessibility, further driving growth in this segment. The rising prevalence of genetic disorders and a growing understanding of the role of TTR in amyloidosis have also highlighted the significance of effective management strategies.
Given the complexity of symptoms associated with TTR Familial Amyloid Polyneuropathy, early diagnosis, and intervention have become key focus areas for healthcare professionals, thereby positively influencing the India Transthyretin Amyloidosis Market dynamics. As awareness increases in both the medical community and among patients regarding the implications of this condition, it is anticipated that community outreach and education will further refine treatment paradigms, optimizing patient outcomes. Thus, the Disease segment related to TTR Familial Amyloid Polyneuropathy is poised to play a central role in shaping the future of the India Transthyretin Amyloidosis ecosystem, guided by advancements in science and a commitment to improving healthcare standards across the sector.This continuous growth and nurturing of knowledge around TTR-related disorders reflect both the challenges and opportunities that lie ahead in the management of such complex diseases, reinforcing the need for a strategic approach to market segmentation and targeted therapeutics.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The India Transthyretin Amyloidosis Market shows distinctive gender-related patterns, highlighting important trends in the disease's prevalence and management. Males are often observed to have a higher incidence of transthyretin amyloidosis, leading to a notable market interest in male-oriented treatments and therapeutics. However, females also represent a significant portion of the patient population. They are increasingly being targeted for tailored therapies, driven by the growing recognition of their unique health profiles and needs regarding this condition.
This differentiation contributes to the overall market segmentation, which reflects varying treatment approaches and healthcare responses. The trends within the India Transthyretin Amyloidosis Market signify a shift towards more specific and inclusive healthcare solutions. The awareness campaigns and education initiatives aimed at both genders are expected to drive early diagnosis and improve patient outcomes. Additionally, advancements in research targeting gender-specific responses to therapies offer promising avenues for market growth as healthcare providers seek to optimize clinical management strategies for both males and females, ensuring that both groups receive the necessary attention in their treatment paradigms.
The Treatment segment of the India Transthyretin Amyloidosis Market focuses on various therapeutic approaches aimed at managing this condition effectively. Among these approaches, Small Molecule Treatment has gained prominence due to its targeted mechanism of action and ability to penetrate cellular membranes, thereby addressing the underlying pathology of transthyretin amyloidosis. This method often offers a favorable safety profile and is associated with improved patient compliance compared to traditional biologics. As awareness around transthyretin amyloidosis increases in India, driven by educational initiatives and advancements in diagnostic techniques, the demand for effective treatments is also expected to rise.
The Indian healthcare ecosystem, supported by government efforts to enhance access to innovative therapies, is paving the way for the introduction of Small Molecule Treatments, which are anticipated to become a significant component of the therapeutic landscape. The increasing focus on precision medicine further underscores the importance of such treatments, as they provide tailored options for patients based on their unique genetic and clinical profiles. Overall, Small Molecule Treatment is positioned to play a critical role in the ongoing evolution of the India Transthyretin Amyloidosis Market, addressing unmet needs and contributing to improved health outcomes.
The India Transthyretin Amyloidosis Market, under the End-User segmentation, reflects strong demand in various healthcare settings, particularly within Ambulatory Surgical Centers and Clinics. These healthcare environments are pivotal as they facilitate early diagnosis and treatment for patients suffering from transthyretin amyloidosis, thereby improving patient outcomes. Ambulatory Surgical Centers play a vital role in providing specialized, outpatient surgical care with enhanced efficiency, catering to the increasing patient population. Similarly, Clinics offer accessible healthcare options, emphasizing the importance of early intervention and ongoing management of the disease.
The rise in awareness about transthyretin amyloidosis among healthcare professionals and patients is essential, leading to a growing preference for treatment options available in these facilities. As advancements in diagnostics and therapeutic strategies continue to evolve, the role of these End-User categories becomes increasingly significant in the overall landscape of the India Transthyretin Amyloidosis Market, illustrating their critical contribution to disease management and patient care.
The India Transthyretin Amyloidosis Market is experiencing notable growth as awareness of this rare disease increases among healthcare professionals and patients alike. Transthyretin Amyloidosis is a condition caused by the misfolding of the transthyretin protein, leading to the deposition of amyloid fibrils in various organs, including the heart and kidneys, which can cause severe complications. The competitive landscape in this market is characterized by the presence of several pharmaceutical companies engaged in research and development, manufacturing, and distribution of innovative therapies aimed at addressing this condition. As the demand for effective treatment options surges, companies are focusing on expanding their product pipelines, strengthening collaborations, and enhancing their market strategies to capture a more significant share of this niche market.
Pfizer has established a strong presence in the India Transthyretin Amyloidosis Market through its innovative treatment solutions and extensive distribution networks. The company has been proactive in its clinical research efforts, leading to the development of therapies that target the underlying mechanisms of Transthyretin Amyloidosis. Pfizer's commitment to raising awareness about the disease, along with its established relationships with healthcare providers, has bolstered its position in this market. Additionally, the company’s strong financial backing enables it to invest in further R&D initiatives, thereby enhancing its product offerings. Pfizer's relentless pursuit of excellence in addressing unmet medical needs positions it favorably against competitors, ensuring that it remains a key player in the treatment landscape for Transthyretin Amyloidosis in India.
Roche has been a significant contender in the India Transthyretin Amyloidosis Market, known for its dedication to delivering key therapeutic solutions for patients suffering from this rare disease. The company offers various products aimed at managing symptoms and improving the quality of life for patients affected by Transthyretin Amyloidosis. Roche’s strong market presence in India is attributed to its robust product lines, which are backed by extensive clinical data supporting their efficacy and safety. Moreover, Roche is actively engaged in partnerships and collaborations to enhance its research capabilities and expand its market reach. The company has also made strategic acquisitions in the past that have reinforced its portfolio in this therapeutic area. Roche’s focus on innovative approaches and patient-centric strategies solidifies its strengths and enhances its competitive edge in the dynamic landscape of the India Transthyretin Amyloidosis Market.
In recent developments within the India Transthyretin Amyloidosis Market, innovative therapies and increased awareness have begun to enhance patient outcomes significantly. Companies such as Pfizer and Alnylam Pharmaceuticals have made notable advancements in their therapeutic offerings, contributing to the growth of this specialized market segment. In November 2022, Eisai announced collaborations to enhance their treatment protocols, further establishing their presence in India. The market is also witnessing growth in valuation as healthcare infrastructure improves, signaling a rising demand for efficient diagnosis and treatment of transthyretin amyloidosis, particularly among older populations in the country. Additionally, there is reported interest in local partnerships by multinational corporations like Roche and Novartis to cultivate Research and Development initiatives aimed at localizing therapies, ensuring they cater effectively to the Indian demographic. While there haven't been publicly acknowledged mergers or acquisitions affecting the market in the past few months, the push for partnerships remains a vital theme as companies seek to expand their footprint in India. Overall, the progression in therapeutics and rising investments in healthcare infrastructure are shaping a promising future for transthyretin amyloidosis treatment in India.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 335.0(USD Million) |
| MARKET SIZE 2024 | 365.0(USD Million) |
| MARKET SIZE 2035 | 847.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.953% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Pfizer, Roche, Eisai, Boehringer Ingelheim, Celgene, Novartis, Amgen, Daiichi Sankyo, Ionis Pharmaceuticals, Mitsubishi Tanabe Pharma, Sobi, AstraZeneca, Teva Pharmaceutical Industries, Bristol Myers Squibb, Alnylam Pharmaceuticals |
| SEGMENTS COVERED | Disease, Gender, Treatment, End-User |
| KEY MARKET OPPORTUNITIES | Increasing prevalence awareness campaigns, Emerging diagnostic technologies, Development of targeted therapies, Collaborations with healthcare providers, Market expansion in rural areas |
| KEY MARKET DYNAMICS | Rising patient awareness, Improving diagnostic capabilities, Increased research funding, Growing treatment options, Aging population prevalence |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The India Transthyretin Amyloidosis Market is expected to be valued at 365.0 million USD in 2024.
By 2035, the India Transthyretin Amyloidosis Market is projected to reach a valuation of 847.0 million USD.
The expected CAGR for the India Transthyretin Amyloidosis Market from 2025 to 2035 is 7.953%.
The Transthyretin (TTR) Familial Amyloid Polyneuropathy segment is expected to be valued at 300.0 million USD in 2024.
This segment is projected to grow to 700.0 million USD by the year 2035.
Major players in the market include Pfizer, Roche, Eisai, and Novartis among others.
Emerging trends include advancements in therapeutic options and increased awareness about Transthyretin Amyloidosis.
The growth of this market is expected to enhance treatment options and improve patient outcomes within the healthcare system.
The market segments are anticipated to grow in alignment with the overall CAGR of 7.953% from 2025 to 2035.
The India Transthyretin Amyloidosis Market is uniquely positioned due to its increasing patient base and expanding healthcare infrastructure.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
